A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder
Phase 2 – studying effectiveness and dosage
Conditions:
Major Depressive Disorder
Sponsor: Draig Therapeutics Limited
trial.available_in:
БГ
Overview
Trial status: Authorised
This will be assessed by reviewing the change in the participants score of the depression rating scale called Montgomery Åsberg Depression Rating Scale (MADRS)
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 113 participants
БГ